Format

Send to

Choose Destination
J Rheumatol. 1998 May;25(5):896-9.

A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.

Author information

1
Department of Rheumatology, Charing Cross Hospital and Kennedy Institute of Rheumatology, London, England, UK.

Abstract

OBJECTIVE:

To establish whether there is a place for low dose azathioprine (AZA) as a disease modifying agent in patients with uncomplicated primary Sjögren's syndrome (SS).

METHODS:

Twenty-five patients with primary SS were entered into a double blind, placebo controlled trial of AZA (1 mg/kg/day) for a period of 6 months.

RESULTS:

Six patients, all receiving active drug, withdrew because of side effects. There was no significant change in disease activity variables when measured clinically, serologically, or histologically.

CONCLUSION:

This trial suggests that low dose AZA does not have a role as a disease modifying agent in SS.

PMID:
9598887
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center